Boston Scientific's new round of troubles leads Goldman Sachs to cut its rating to sell, while adjusting the rating on rival St. Jude Medical and revising higher the price target on shares of Medtronic.
MarketWatch.com - Top Stories, MarketWatch
Tue, 03/16/2010 - 7:22am
Boston Scientific's new round of troubles leads Goldman Sachs to cut its rating to sell, while adjusting the rating on rival St. Jude Medical and revising higher the price target on shares of Medtronic.